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ABSTRACT
Modeling the Long Term Effects of Alendronate on Bone Mass Preservation of
the Femur with Articular Surface and Total Hip Replacements
Trevor Hryce

Calculating femoral bone density changes after hip arthroplasty is of
interest to researchers and clinicians for predicting the longevity of the prosthetic
implant and the surrounding bone. Recently clinicians have been administering
bisphosphonate drugs in an attempt to reduce the bone resorption due to stress
shielding caused by these implants. Current strain-adaptive computational
models with bisphosphonate treatment don’t predict the long term effects or look
at treatment with hip resurfacing implants. The main goal of this study was to
create and validate a computer model of the human femur incorporating a bone
remodeling algorithm based on biological remodeling processes and
bisphosphonate drug treatment. A secondary objective was to then create
various bisphosphonate drug treatment scenarios and evaluate differences in
bone density, damage, and activation frequency. Experimental studies were
used to validate the model and the effects of bisphosphonates. A finite element
model created from a CT scan of a cadaveric femur, a bone remodeling
algorithm, and a bisphosphonate algorithm were incorporated into the model with
loading conditions representative of walking and stair climbing. The model was
allowed to evolve from an initial state of homogenous density to a steady state
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form with a density similar to that of the femur. Reduced loading representative
of decreased muscle forces were applied to the steady state form to simulate
preoperative conditions of a patient with hip osteoarthritis. Both a femoral hip
resurfacing component and an uncemented, tapered stem were then integrated
in the computer model representative of a postoperative state. Bisphosphonate
treatment was applied to both the preoperative and postoperative states in
several scenarios after untreated simulations. Bone loss was predicted over a
six year postoperative period for both implants and varying treatments. Femoral
bone loss in bisphosphonate treatment scenarios matched results seen clinically.
Bone volume fraction (BVF) showed little change between one year preoperative
to one year postoperative Alendronate treatment and one year postoperative
Alendronate treatment for a specific implant type. Both treatment scenarios
increase the BVF over no treatment. Pretreating with Alendronate appears to
help against femoral neck fracture. This study successfully created a threedimensional finite element model able to simulate long term effects of the
remodeling process in bone with Alendronate treatment. The results show an
importance of treatment timing for both types of implants especially when
potentially requiring a revision surgery.
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1. Introduction
1.1. Purpose
A primary concern following total hip arthroplasty is the bone loss in the
proximal femur [1, 2]. Part of the bone loss is due to stress shielding, where the
implant takes up a majority of the load applied and transfers it to distal bone,
creating lower than normal strains on the surrounding bone in the proximal
aspect. This bone experiencing lower strain remodels, and decreases the bone
density for that area increasing the periprosthetic fracture risk and contributing to
implant loosening [3-5]. This decrease of bone density means less bone stock
and other options for revision surgery [6].
Newer uncemented, tapered, titanium stems have shown less bone loss
over long-term than similar uncemented straight stems [7, 8]. In addition, metalon-metal hip resurfacing retains bone stock in the proximal aspect of the femur,
making it easier to convert to a total hip arthroplasty in revision surgery [9]. This
is especially important for younger patients with hip osteoarthritis who may need
several revision surgeries. Resurfacing arthroplasty is also believed to maintain
a more natural loading state in the proximal femur. Recently a group of drugs
called bisphosphonates have been administered in conjunction with hip
arthroplasty [10, 11]. Normally used to help prevent bone mineral density loss in
osteoporosis, bisphosphonates are being used in an attempt to prevent the bone
loss in the proximal aspect of the femur after hip arthroplasty.
Computer models that accurately simulate bone remodeling could be
useful in comparing bone loss following arthroplasty surgeries with
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bisphosphonate treatment because it’s not always possible to accurately
measure bone mass density changes clinically. Existing computer models don’t
incorporate the underlying biological process of a basic multicellular unit that is
responsible for bone’s adaptation in response to environmental loading changes
while looking at the long term bisphosphonate effects. Existing models also do
not look into modeling the effects with the use of a surface replacement
arthroplasty.
The goal of this project is to integrate bisphosphonate drug treatment into
a computer model with a bone remodeling algorithm based on the biological
remodeling process to explore the problem of bone loss following hip
arthroplasty. The objectives of this study are to: (1) validate the implementation
of a previously developed computer model into the current study, (2) implement
bisphosphonate code into the model, (3) perform and validate long term
computer simulations to study the mechanisms of bone loss in the proximal
aspect of the femur for an uncemented tapered stem and a resurfacing
component under the effects of Alendronate, and (4) evaluate different
Alendronate treatment scenarios.
1.2. Bone Structure
Bone is a dynamic tissue made of collagen, water, hydroxyapatite mineral,
proteoglycans, and noncollagenous proteins that constantly adjusts to its
mechanical and physical environment through changes in the microscopic
architecture and composition [12]. The nonmineralized space in bone contains
marrow which is a tissue composed of nerves, blood vessels, and other cells.
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The remaining bone is mineralized and split into two different types determined
by porosity. Most bone tissue is either very low porosity or very high porosity.
The low porosity bone is known as compact bone while the high porosity is
known as trabecular bone.
Compact bone forms the cortex for long bones and has a porosity of 510%. The pores are categorized as either Haversian canals, Volkmann’s canals
or resorption cavities. Haversian canals align with the long axis of bone and
contain the nerves and capillaries. Volkmann’s canals also contain capillaries,
and are transverse canals which connect Haversian canals to each other and to
the outside of bone. Resorption cavities are the spaces temporarily made by
osteoclasts during bone remodeling.
Trabecular bone is normally found at the end of long bones as well as flat
bones and cuboidal bones and has a porosity of 75-95%. The pores are filled
with marrow and the bone matrix forms struts called trabeculae that often seem
randomly arranged. Important features of both types of bone can be seen in
Figure 1-1.
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Figure 1-1 shows important features of a typical long bone [12].

Both types of bone contain two major bone tissue types. Lamellar bone is
highly organized and slow forming bone, consisting of layers called lamellae
which create a matrix of collagen fibers and minerals. This calcified matrix
surrounds the Haversian canals in concentric rings which is also called an
osteon. Woven bone is poorly organized and quick forming bone where the
matrix of collagen fibers and minerals is more randomized.
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1.3. Bone Remodeling
Within the cortex of bone, basic multicellular units (BMUs) initiate osteonal
bone remodeling. BMUs are the coupling of osteoclasts and osteoblasts working
in teams with a central Haversian canal providing the pathway for capillaries to
supply needed nutrients which can be seen in Figure 1-2. BMUs are activated
by a stimulus such as damage or disuse. Osteoclasts are multinucleated cells
formed from monocytes that resorb bone. The osteoclasts demineralize bone
with acid and dissolve collagen with enzymes [12]. Normally it takes about three
weeks to resorb the bone perpendicular to the path of the BMU. Osteoblasts are
mononuclear cuboidal cells that differentiate from mesenchymal cells.
Osteoblasts produce the organic portion of the bone matrix [12] and refilling the
resorption space takes about three months but may take up to six months to
completely mineralize. During the remodeling process, osteoblasts can be
buried inside cavities, called lacunae, in the newly formed bone and can become
osteocytes. Osteocytes communicate to each other and other osteoblasts
through tunnels called canaliculi. The whole remodeling process maintains
existing bone or changes the porosity, and can realign the trabeculae of
trabecular bone.
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Figure 1-2 shows the coupling action of both osteoclasts and osteoblasts which make up a BMU
[13].

1.4. Osteoporosis
Osteoporosis is defined as a disease characterized by low bone mass and
microarchitectural deterioration of bone tissue leading to enhanced bone fragility
and a consequent increase in fracture risk [14]. Most notably, the vertebra, hip
and wrist bones become porous and weak, making them susceptible to fracture
after minimal forces or pressure. The underlying mechanism is an imbalance
between an increased resorption of bone and decreased formation of bone, and
normally presents itself in low trauma fracture, backache, height loss, spinal
deformity, or in radiological bone mineral density [15]. An example of bone
microarchitectural deterioration can be seen in Figure 1-3.

6

Figure 1-3 shows scanning electron micrographs to show the structure of L3 vertebra in
a 31 year old woman (top) and in a 70 year old woman (bottom) [15].

Some risk factors of osteoporosis include sex and race, age, early
menopause, family history of osteoporosis, lack of estrogen, poor calcium intake,
smoking, heavy alcohol or caffeine consumption, and a lack of exercise [16-18].
Women are at most risk due to a lower peak of bone mass, an increased bone
loss at menopause, and a higher life expectancy [15]. The risk for a fracture
7

increases dramatically with age, decreasing the lifespan and increasing the
mortality rate [15].
The treatment of osteoporosis is based upon bone mineral density in the
spine and proximal femur using a dual energy x-ray absorptiometry (DXA). To
be diagnosed with osteoporosis, a bone mineral density of 2.5 or more standard
deviations away from the normal peak bone mass must be observed. DXA is
used primarily because it is fairly inexpensive, involves low radiation exposure,
and can measure bone density accurately in areas where fractures are the most
common [17].
Ideally, people want to prevent osteoporosis by optimizing their skeletal
bone mass throughout life, and to keep bone mineral density levels as close to
peak levels as possible. Doing this can be accomplished by taking actions aimed
at the risk factors outlined above. Therapeutic options now exist for those who
are diagnosed with osteoporosis. Some of these options include
bisphosphonates, raloxifene and hormone replacement therapy, strontium
ranelate, and parathyroid hormone peptides.
1.5. Bisphosphonates
Bisphosphonates are related to pyrophosphate in which the oxygen bridge
is replaced by a carbon with various side chains. They were developed and used
in the treatment of bone disease after being discovered that they effectively
control calcium phosphate formation and dissolution as well as mineralization
and bone resorption in vivo. Bisphosphonates bind strongly to the bone mineral,
hydroxyapatite, which explains the mode of action for the drug. Deposits form
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where bone mineral is exposed to surrounding fluids, especially areas of bone
formation and resorption. The release of bisphosphonates in the body is
primarily when the bone is being resorbed again. Otherwise, due to the chemical
backbone of bisphosphonates (P-C-P group) being enzymatically resistant seen
in Figure 1-4, the body is unable to metabolize the compound and they are
excreted by the kidneys without alteration. The charge and the size of the
bisphosphonate limits the penetration through different cellular membranes [19].

Figure 1-4 shows the common bisphosphonate chemical backbone.

Effects of bisphosphonates can be separated into several categories. At
the tissue level, bisphosphonates reduce bone turnover by decreasing both bone
resorption and bone formation. Since there is a negative balance at each BMU,
a decrease in the turnover leads to a decrease in bone loss. There isn’t
evidence of reduction of osteoblast activity at each site however, so the amount
of bone formed at each BMU is not decreased, but increased. Also, after a
decreased turnover, newly formed bone has more time to complete
mineralization since there’s less chance of it being remodeled. Both these create
an increase in the amount of bone in humans. At the cellular level, the final
target of bisphosphonates is the osteoclast. Different ways of reducing
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resorption by the osteoclast include inhibition of recruitment to the bone surface,
inhibition of activity at the bone surface, shortening of the lifespan, or alteration of
the bone mineral in ways which reduce the rate of dissolution. At the molecular
level, it’s possible bisphosphonate action on a cell surface or bisphosphonate
uptake by the cell interacts with an enzyme or other molecule, affecting cellular
metabolism [19].
The potency of bisphosphonates depends on the side chains connected to
the backbone, and typically are separated into either a nitrogenous groups or a
non-nitrogenous group. Those with a nitrogen side group are considered to be
the most potent. One example of a potent bisphosphonate is Alendronate
(commercially known as Fosamax). Alendronate (C4H12NO7P2Na·3H2O) is
considered a first line option and normally taken orally when fasting, however it
can be taken intravenously as well [15]. Some adverse effects include upper
gastrointestinal intolerance [20] as well as auditory, visual, and olfactory
hallucinations [21]. The chemical structure of Alendronate can be visualized in
Figure 1-5.

Figure 1-5 shows the chemical formula for Alendronate
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1.6. Osteoarthritis
Osteoarthritis is the most common type of arthritis, estimated in12.1% of
the adult population and about 20% of people above the age of 65 will be at high
risk in the year 2030 [22]. Before 1986 osteoarthritis was regarded as a
degenerative disease involving articular cartilage and subchondral bone but it
has become viewed as a syndrome with many complex etiologies [23].
Osteoarthritis is currently characterized physiologically by focal areas of damage
to the articular cartilage, changes in the subchondral bone, as well as synovitis
and capsular thickening [23]. Radiographs help to see the joint space, as seen in
Figure 1-6, and changes of subchondral bone but people with severe
radiographic change can still be symptom free. Symptoms normally include pain,
stiffness after activity, popping, and swelling of the joint. Women are at higher
risk than men and the risk increases with age as well. Therapies for
osteoarthritis include lifestyle modification and pharmacological treatment before
the long term solution of a joint surgery [22, 23].
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Figure 1-6 shows a radiograph of a patient with hip osteoarthritis.
http://chicopmr.org/pain/images/hip-xray-osteoarthritis.jpg

1.7. Hip Arthroplasty
Hip arthroplasty is the artificial replacement of the joint which connects the
pelvis to the femur. In order to recreate the ball and socket joint, both the femur
and acetabulum have parts surgically removed. On the femur, the head and part
of the neck is removed in order to fit a metal stem into the medullary canal which
can be seen in Figure 1-7.
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Figure 1-7 shows the removed parts of the femur to incorporate a total hip replacement
[24].

On top of the stem sits a metal ball, normally composed of cobalt
chromium, to replicate the femur head. A small part of the acetabulum is
removed in order to fit a metal cup lined with ultra-high molecular weight
polyethylene (UHMWPE) for the replicated femur head to fit into. This cup can
be seen in Figure 1-8.
When early metallic implants made of cobalt chrome started to be used,
femur designs used bone cement made of polymethylmethacrylate (PMMA) to
help secure the fixation. While the cement did initially aid in fixation of the
13

femoral implant, the interfaces of the cement with both bone and implant failed,
leading to high loosening rates [25] causing further damage to the bone.
Due to the high loosening rates, uncemented implants were used more.
Using a larger diameter stem with a press fit into the bone created a strong
fixation and solved the problem with the bone cement. Unfortunately, the new
design structure of the stem with increased size and high stiffness caused stress
shielding. To address the high stiffness, more flexible titanium stems with a
proximally porous coating to allow for bone to grow into the stem were used and
determined to lead to less bone resorption compared to the cobalt chrome with
extensive porous coating [26, 27]. The stem used in this study, seen in Figure 18, is an uncemented, tapered, titanium stem which has shown less bone loss
long term than similar uncemented straight stems.
Even with improvements in fixation and in the bearing of surfaces, total hip
arthroplasty did not have encouraging results for all patients. Articular surface
replacement became popular due to a larger demand from younger, more active
patients [28] for the preservation of bone stock as well as less stress shielding in
the proximal femur because of the possible need for revision operations [29].
Resurfacing the femur involves removing part of the femur head and covering it
with a hemispherical shell with a short stem as seen in Figure 1-9. Early
material for articular surface replacement by Smith-Petersen tried using glass,
due to its inertness, and viscaloid, which ended up causing too much foreign
body response [30] before a cobalt chrome alloy was introduced later.
Resurfacing in the 1970’s started using a metal stem with a polyethylene
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acetabular cup but long term studies showed high failure rates [29] due to
loosening which caused wear debris, initiating a foreign body response [31].
Within the past 10 years, resurfacing has become even more popular due to
better manufacturing techniques [32]. The new components use metal femoral
and acetabular parts, reducing the wear and failure rates [32], however there are
some concerns about the implantation procedure and fracture risk of which the
mechanism is unknown [33]. It also is not possible to measure bone mineral
density changes within the femoral head and certain regions of the femoral neck
using DXA scans. These metal on metal implants have demonstrated short term
success [29] but much about the wear debris and long term success are still
unknown.
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Figure 1-8 shows the Biomet Taperloc stem (left) and Depuy ASR femoral component
(right) that were used in this study. Radiographs of an implanted hip resurfacing
component (top right) and an uncemented, tapered stem (bottom right). Acetabulum
components can be seen in both radiograph images [34].
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Figure 1-9 shows the resurfaced femur (top) with an ASR implant (bottom) [24].
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Recently, bisphosphonates like Alendronate have been used with hip
replacements to help against stress shielding. The bisphosphonates are used in
order to preserve the bone mass of the femur, however their anti-resorptive
action may lead to increases in fatigue microdamage.
1.8. Previous Remodeling Simulations
Many algorithms to explain the architecture and properties of bone have
been developed based on the observations by Wolff which resulted in his
hypothesis known today as “Wolff’s Law” [35]. Wolff states that bone has the
adaptive property to change its architectural shape and external form in response
to mechanical stimuli, limited to certain mathematical rules. Since modeling rates
slow down significantly more compared to remodeling rates when reaching
skeletal maturity [12], most algorithms focus on predicting bone changes due to
remodeling.
Cowin et al. created an algorithm for the adaptive process of bone
describing it as an elastic material which adapts structurally to an applied loading
[36]. This model maintains a level of bone strain through either modeling or
remodeling processes to adjust the density of cortical bone. Taking this adaptive
elasticity model further, Huiskes created an algorithm that would model or
remodel bone in order to maintain a constant level of strain energy density [37].
A schematic of this algorithm can be seen in Figure 1-10.
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Figure 1-10 shows a schematic representation of the adaptive remodeling program
integrated with finite element method (FEM) code. The feed-back control variable is the
difference between the actual strain energy density (SED), the apparent strain energy
density U, and homeostatic SED, Un.

Implementing this algorithm with a prosthesis used in total hip
arthroplasty, the effects of stress shielding on bone loss based upon the loaded
implant was modeled two-dimensionally. They created a set threshold for
homeostatic strain energy density, and an increase or decrease outside this
range results in bone gain or loss, respectively. The two dimensional model then
incorporated these effects by modeling straight stem implants of increasing
diameter subjected to loading in a straight bone shaft. The model representation
created was adequate enough to describe the three-dimensional structural
integrity of the bone. The study also helped predict the effects of stem rigidity
and degree of fixation related to stress shielding as can be seen in Figure 1-11.
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Figure 1-11 shows predicted bone loss around varying stem sizes using the strain
adaptive algorithm created by Huiskes et al. [37]

Continuing with this work, Huiskes et al. [38] looked at a two-dimensional
model to describe the post-loosening mechanical behavior of surface
replacements. The cup was modeled with linear beam elements in the frontal
plane and spanning beam elements in the medial and lateral sides that
corresponded to a solid model showing equivalence. A bi-linear stress-strain
behavior, low elastic modulus, and gap elements were used to model the fibrous
tissue. The results indicate that high failure rates are correlated indirectly with
the implant design to implant loosening and the propagation of bone resorption
and fibrous tissue formation. This suggested that the ability of these implants to
obtain a stable post-loosening configuration is an important design criterion for
the long-term survival.
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Furthering the algorithm use, Huiskes et al. [39] looked at the relationship
between stress shielding and bone resorption around total hip stems and the
effects of flexible materials in a three-dimensional model. They found flexible
stems reduce stress shielding and bone resorption but they increase the proximal
surface stresses. The findings also supported the hypothesis that resorption
processes are an effect of bone adaptation to stress shielding and individual
variations in bone reactivity and mechanical bone quality may account for the
individual differences found in experiments.
Another algorithm created by Beaupre et al. [40] determined the net
resorption and formation by taking the difference between the stimulus and the
tissue attractor state. The attractor state is the level of daily loading necessary to
maintain bone at a known density. They use a time dependent approach for
modeling and remodeling, taking into account the amount of bone surface area
both osteoclasts and osteoblasts can work. The model uses local signals which
don’t necessarily lead toward global optimization. Each bone site optimizes its
own environment instead of towards the structure as a whole. This means during
normal aging, local changes made by modeling and remodeling never stop,
indicating the model never converges just like actual bone. However, the rate of
change will diminish as each site reaches the attractor state. A diagram of their
remodeling code can be seen in Figure 1-12.
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Figure 1-12 shows a block diagram representation of bone remodeling with multiple
feedback loops created by Beaupre et al. driven by local, not global signals [40].

A three-dimensional, iterative model by Van Rietbergen et al. [41] used
the site formulation theory as well. This theory assumes the treated bone with an
implant attempts to normalize its stress-strain patterns to the same value as the
untreated bone [37]. They also incorporate Martin’s theory [42] that says bone
apposition and resorption can occur only at free bone surfaces. Bone mass is
regulated by elastic strain energy per unit mass, and when the difference
between the treated bone and untreated bone reaches a certain threshold, no
remodeling takes place and the model converges. More recently, Gupta et al.
[43] uses this adaptive bone remodeling theory to assess the short term risk of
femoral neck fracture (1-2 years) and long term risk of failure of fixation (5 years)
of a cemented resurfacing femoral head. Results showed strain shielding in the
femoral head with a 50-90% reduction in bone density in the superior femoral
head region and elevated strains of 0.50 – 0.80% generated in the superior
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femoral neck. These high strains only occurred in a small fraction of bone
indicating a low risk of fracture post-surgically and the strains were considerably
reduced after bone remodeling leading to an even smaller chance of fracture.
Peter et al. [44] takes a remodeling algorithm and adds in bisphosphonate
treatment. The model developed takes into account bone inhomogeneity and
bone transverse isotropic symmetry by using relative density and an anisotropy
tensor. For this short term simulation, the bone density is linked to the
mechanical stimulus in a linear relation and the tensor is kept constant. To
simulate the drug, the resorption parameters are affected with the formation
parameters kept constant.
1.9. Remodeling Algorithm
The remodeling algorithm used in this study was developed by Hazelwood
et al. [45] and models the activity of basic multicellular units (BMUs) responsible
for resorbing and depositing bone through activation by both disuse and fatigue
microdamage. A schematic of this algorithm can be seen in Figure 1-13.
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Figure 1-13 shows a schematic representation of the bone remodeling algorithm
developed by Hazelwood et al. Remodeling is activated by disuse and damage and the
porosity is determined from the activation frequency history [45].

The model can adapt its porosity over time in local areas of disuse or
damage throughout the entire bone since it simulates BMU behavior. In the
remodeling code, the rate change in porosity ( ) is the difference between the

resorbing and refilling rates.

(1)
The resorption rate (

(

(

) is the product of the resorption rate per BMU

and the number of resorbing BMUs/area (

). Similarly, the refilling rate

) is the product of the refilling rate per BMU (

BMUs/area (

) and the number of refilling

). The number of BMUs resorbing and refilling varies as a
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function of BMU activation frequency. The resorption (

(

) and refilling

) rates are calculated by the average area resorbed or refilled per

BMU ( ) divided by the resorption or refilling time period (

respectively).

Net bone resorption occurs during disuse and initially during microdamage
removal. Activation frequency ( ) is defined as the sum of the activation

frequency due to disuse (

(

) and the activation frequency due to damage

), multiplied by the specific surface area ( ). The specific surface

area is the free internal surface area per unit volume that’s available for
remodeling and uses normalized values between 0 and 1.

(2)
Damage ( ) is defined as a crack length per area of bone. The rate of

fatigue damage is described as the difference in fatigue damage formation (

and removal (

) rates.

(3)
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)

The fatigue damage formation rate (

) is assumed to be proportional to the

product of the strain ( ) raised to a power ( ) and the loading rate (

over

) summed

loading conditions [46].

(4)
In this equation,

mechanical stimulus and

represents the summation term and is known as the

is the damage rate coefficient. The exponent

balances the relative importance between strain magnitude and the number of
loading cycles and in the case of this study, a value of 4 is used based on
previous research [40, 45, 46].
If we assume damage and BMUs are random throughout the bone, then
the fatigue damage removal rate (

) would equal the product of damage ( )

and the area fraction resorbed per day (

) where

is the cross sectional area

of a BMU. However in the model, it is assumed damage actually initiates BMU
activation which means the damage removal rate would be greater than random
remodeling. Since the rate would be greater, a specificity factor ( ) was

included.

(5)
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Disuse for the model is defined as a level of mechanical stimulus ( )

below the equilibrium stimulus (

). To model the effects of disuse, BMU

activation frequency is increased when below a given stimulus threshold and the
refilling rate is reduced as well [47]. The relationship between activation
frequency due to disuse and activation frequency due to damage are assumed
sigmoidal which enables activation frequency calculation. Once calculated, the
number of resorbing and refilling BMUs can be determined, followed by the rate
of change in porosity (Eq. 1).
1.10.

Bisphosphonate Algorithm

The bisphosphonate effects for this study are modeled according to code
implemented by Nyman et al [48, 49]. This treatment reduces activation
frequency [19, 50-52] as well as the resorption cavity size [19, 51-53] to account
for Alendronate. The potency of suppressing the activation frequency is a
function of the number of resorbing BMUs.
(6)
where Pmax is the maximum suppression coefficient,

is the rate of suppression

coefficient, and NR is the number of resorbing BMUs. Both variables reflect the
dosage and structure of the bisphosphonate. Nyman incorporated this
bisphosphonate code into a two-dimensional model for knee arthroplasty to
investigate the long-term effects to minimize proximal bone loss and found
bisphosphonate treatment to slow the rate of bone loss by 42% after one year as
seen in Figure 1-14 [48].
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Figure 1-14 shows that the rate of bone loss after total knee arthroplasty below the tibial
tray is slower when bisphosphonate effects are simulated than without treatment [48].

1.11.

Finite Element Analysis Modeling

Algorithms can be integrated into finite element models that have a
variable modulus as a function of bone density because changes in strain drive
the remodeling process. Previously, studies have been performed to examine
postoperative changes in femoral bone density to evaluate effects of different
muscle groups on the remodeling process as well as changes following hip
arthroplasty [43, 54, 55]. Deuel improved the current three-dimensional femur
models by implementing the remodeling algorithm by Hazelwood et al. in order to
incorporate the biological mechanism of remodeling to study changes in bone
density following total hip and hip resurfacing arthroplasty procedures.
The previous simulations using this algorithm were performed with a twodimensional model by Hazelwood and Mizumoto [56]. The model was created
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from a radiograph and used joint reaction and abductor muscle forces which
originally started in a homogenous bone density distribution. With the
remodeling algorithm, the model was allowed to evolve until reaching a steady
state condition. Bone loss predictions by the model were consistent with the
measurements clinically found after surgery.
Similarly, Nyman et al. [57] incorporated the remodeling algorithm into a
two-dimensional finite model of the tibia to investigate bone loss following total
knee arthroplasty (TKA). The model predicted most bone loss to happen during
the first six months following surgery which was also consistent with clinical
findings.
1.12.

Current Model

The femur model created by Deuel et al. [34] was created from a CT scan,
using a LightSpeed QXi CT scanner, (GE Healthcare, Milwaukee, WI) of a male
cadaveric femur with soft tissue removed. Mimics (Materialise USA, Ann Arbor,
MI) was used to create the initial two-dimensional surface mesh from the scan
which was then imported into Patran (MSC Software Corporation, Santa Ana,
CA) and converted into a three-dimensional mesh using second order tetrahedral
elements. A convergence study was then performed using a simplified loading
scheme of hip joint and abductor forces to compare principle strains and
displacements and enable an appropriate mesh density selection. The finite
element solver Abaqus (Simulia, Providence, Rhode Island) was used for all
analyses.
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Two similar meshes of the native femur were created to allow the removal
of elements for both the resurfacing implant and tapered stem. For the native
femur used in the tapered stem model, the finite element mesh consisted of
45,691 elements and 63,986 nodes and for the resurfacing implant the mesh
consisted of 29,175 elements and 41,723 nodes. This original model consisted
of a solid mesh with elements having homogeneous material properties based on
experimentally measured values of cortical bone.
Three load cases during the single stance phase of walking and stair
climbing were used in the model for hip joint contact and muscle forces. These
cases included the loading during heel strike and toe-off phases of normal
walking and maximum forces during stair climbing. Normal activity levels of
patients with normal functioning total hip replacements included 5000 daily
loading cycles during walking and 20 daily cycles for stair climbing. Using a body
weight of 836 N based on the weight of a typical patient undergoing total hip
arthroplasty surgery, magnitudes and directions of hip joint and abductor muscle
forces were calculated to determine appropriate joint loading angles during
walking and stair climbing as can be seen in Figure 1-15. Only the gluteus
medius, gluteus minimus, adductor longus, adductor brevis, psoas, vastus
lateralis, and the vastus medialis muscle groups were used because they have
previously demonstrated to be the most significant influence on strain distribution
and remodeling. The distal region of the femur model was constrained rigidly
above the femoral condyles.
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Figure 1-15 shows anterior (a) and posterior (b) views of hip joint contact and muscle
force magnitudes applied to the model as a percentage of body weight (BW = 836 N) for three
separate load cases: I. heel-strike phase of walking; II. toe-off phase of walking; III. stair climbing.
Force application points represent the approximate centers of distributed loads [34].

The hip replacement models used are a 49 mm resurfacing femoral
component (ASR, DePuy, Warsaw, Indiana) and an 11 x 142 mm uncemented,
titanium, tapered femoral stem with a 32 mm cobalt chrome head (Taperloc,
Biomet, Warsaw, Indiana). With the remodeling algorithm, the models evolved
under loading from its initial homogenous material state until the remodeling
porosity, damage, and activation frequency reached steady state values. Data
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from a comparative experimental study between hip resurfacing versus total hip
arthroplasty were then used to validate the computational finite element model
[24].
After validation, the model simulated reduced loading conditions due to
pain and loss of function because of hip osteoarthritis. Hip joint contact and
muscle force magnitudes were decreased by 6% and the number of loading
cycles was reduced by 20% as well. One year of this reduced loading was used
to describe the preoperative state due to hip osteoarthritis. Following the
preoperative state, either the hip resurfacing or tapered stem components were
introduced to the model. Reduced loading continued for 3 months
postoperatively and then returned to normal but with a continued reduction in
loading cycles by 10% until one year postoperatively. The remodeling simulation
was run for a total of 2 years postoperatively and changes in bone density were
compared between the resurfacing and tapered stem implants using seven
regions of interest defined by Gruen et al. which can be seen in Figure 1-16 [25].

32

Figure 1-16 shows the seven sections around the femoral component for evaluation [25].

Deuel et al. found a 5% mean loss in bone density across all Gruen zones
(GZ) over the one year preoperative period. Implantation of the total hip
replacement showed bone loss most prominent in region 7 with a 24% loss of
bone volume fraction (BVF) at two months and remained approximately 25%
after two years. Damage levels decreased rapidly during the initial postoperative
period and activation frequency increased, indicating strain shielding. Bone
resorption was also observed in zones 6 and 7 and stabilized at about two years.
A reduction in BVF of 8% was observed in region 5 and damage levels increased
over the two years suggesting increased remodeling from damage. Reductions
in BVF of 4% or less were observed in all the other zones. Changes in the BVF
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over the two year period for the total hip replacement can be seen in Figure 117.

Figure 1-17 shows the percentage change in BAF (bone area fraction, equivalent to BVF
assuming normal stereologic conditions [58]) versus postoperative time for the seven
Gruen zones in the total hip replacement [34].

For the resurfacing implant, small amounts of transient bone loss occurred
in all regions within the first two months and nearly returned to preoperative
levels after two years. The maximum loss of BVF in all zones was about 2% or
less. Reductions in bone density were most notable in the superolateral and
inferomedial regions of the femoral head. The inferior region of the femoral neck
showed a transient BVF loss with density decreasing rapidly in the first two
months and then increasing over the next two years, but not returning to
preoperative levels. Damage levels were high and still increasing, but at a
decreased rate in this area. Changes in the BVF over the two year period for the
articular surface replacement can be seen in Figure 1-18.
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Figure 1-18 shows the percentage change in BAF (bone area fraction, equivalent to BVF
assuming normal stereologic conditions [58]) versus postoperative time for the seven
Gruen zones in the articular surface replacement [34].

Using this model and incorporating the bisphosphonate code can give a
better understanding of the long term effects of the femur with both hip
replacement and drug interactions. The aim of the experiment is to incorporate
both of these effects into a user subroutine combined with the finite element
model to compare changes in femoral bone density, activation frequency, and
damage between types of hip implants as well as drug regimens. The trends this
information will show can help physicians decide which type of hip replacement
to use bisphosphonate drugs with and when to administer the drugs.
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2. Methods
2.1. Model Recreation
For the current study, the first step was to recreate the finite element
model simulation by Deuel et al. [34]. This model contained a user material
subroutine (Appendix A) in Abaqus which allowed the model to adapt to different
loading conditions mimicking how bone changes to its loading environment. The
algorithm developed by Hazelwood et al. [45] models BMUs which are
responsible for the resorption and formation of bone after being activated by both
disuse and fatigue microdamage. This allows adaptation of porosity over time in
localized areas of disuse or damage. Porosity in the model can be defined as
the void volume fraction with bone volume fraction (BVF) equal to 1 – porosity.
Increases in damage and loading may result in increased porosity and decreased
density, or BVF, during the lag period. Several small changes were made to the
existing user material subroutine enabling Abaqus to run properly in our
laboratory.
2.2. Model Incorporation and Validation
The model for this experiment included the implants described previously.
The initial mesh was created from a CT scan of an intact cadaveric femur and a
convergence study was performed to select the correct mesh density. Originally,
the intact model was allowed to evolve under loading from its initial homogenous
state until porosity, damage, and activation frequency reached steady state
values, defined by a change of less than 5% over a period of 30 days. The
steady state intact model was validated through clinical experimentation by Deuel
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et al [34]. The steady state intact model then was subjected to reduced loading
conditions lasting for one year, which resulted in the preoperative model. Next,
either the resurfacing or total hip replacement was introduced to the model,
resulting in the postoperative model. Load magnitudes were returned to normal
after three months, but still with a slight reduction in loading cycles until one year
after surgery. After recreating the preoperative and postoperative finite element
models, we validated our current running simulation through Gruen zone
comparisons to results obtained by Deuel et al [34] as well as those obtained
clinically at one and two years.
2.3. Alendronate Code
Using the algorithm by Nyman et al. [49] as described previously (section
1.10), a maximum suppression coefficient (Pmax) of 1.0 and a rate of suppression
coefficient ( ) of 5 reduces activation frequency by a percentage P. Adding in a

reduction in the resorption area by 3/13 observed previously by Chavassieux et
al [50], the complete Alendronate treatment was simulated, corresponding to 10
mg of Alendronate daily [48] or 70 mg weekly [59, 60]. Simulations with these
values give similar results to that observed by dual-energy x-ray absorptiometry
over 7 years in the spines of postmenopausal women who were treated with 10
mg of daily Alendronate [59].
2.4. Alendronate Treatment Scenarios
When implementing the Alendronate treatment, we wanted to look at
differences in treatment times and the results following termination of treatment.
Each simulation ran for a total of six years postoperatively for either the
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resurfacing hip or total hip arthroplasty models and was compared to mean data
from experimental studies. Six years was chosen in order to compare results
with Arabmotlagh et al [59] for long term Alendronate effects. A list of the various
treatment simulations can be seen in Table 2-1. These different treatments were
then compared between each other, between the different types of implants, and
between the non-treatment scenario by looking at differences in damage,
activation frequency, and porosity at specific regions (the Gruen zones) of the
femur. The main comparisons were between the postoperative models having
no treatment, one year of treatment, and six years of treatment and between the
models with one year of postoperative treatment with either no preoperative
treatment or with a full year of preoperative treatment.
Table 2-1 shows the different treatment scenarios for preoperative and postoperative
models. Treatment scenarios were used for both total hip and surface hip replacements.
The main scenarios being compared are the postoperative results with a year of
treatment for each preoperative model treatment.

Preoperative Model Treatment (1
year)

Postoperative Model Treatment (6 years
total)
Six years with no Alendronate
Six years of Alendronate
First year with Alendronate
First year with Alendronate

No Alendronate
One year of Alendronate

2.5. Model Implementation
Models were run on a Dell Precision 490 (N-series) computer (Dell, Round
Rock, Texas) with Red Hat Linux (Red Hat, Raleigh, North Carolina) using
Abaqus version 6.7 (Simulia, Providence, Rhode Island). In order to run a
postoperative model, a text file holding all the state variables is created from the
last step of the preoperative model and is called for in the user material
38

subroutine to initialize the postoperative simulation. The code, created by Deuel
et al, is shown in Appendix B. In order to extract results from our models we use
two files in conjunction. The executable file reads in an .isv file that contains the
model file where we want to extract results, the new file name containing the
results, the starting and stopping steps we want to extract results from, and the
list of elements in the desired Gruen zone that we want data from. The
executable then takes all this information and formats data for activation
frequency, porosity, and damage. This file also allows us to determine the step
interval to extract from. The extracting executable file can be seen in Appendix
C, and the .isv file can be seen in Appendix D.
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3. Results
3.1. Validation
The reduced loading conditions representative of preoperative
changes due to hip osteoarthritis resulted in a 1% mean bone density loss
over all GZ over one year. Further loss of femoral bone density resulted after
implementing the tapered stem into the model. The most prominent bone
loss occurred in GZ 7, seen in Figure 3-1, with about a 24% BVF loss within
two months, and remaining around 25% after two years.

Figure 3-1 shows the postoperative bone volume fraction changes in the seven different
Gruen zones for the total hip replacement validation run. The reference BVF baseline is
taken from the day of surgery.

Damage levels for this zone initially decreased rapidly, seen in
Figure 3-2, while activation frequency increased, seen in Figure 3-3,
indicating an area of strain shielding.
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Figure 3-2 shows the postoperative damage in the seven Gruen zones for the total hip
replacement validation run.

Figure 3-3 shows the postoperative activation frequency in the seven Gruen zones for
the total hip replacement validation run.

41

A reduction in BVF of about 8% could also be viewed in GZ 5. During this
time period, damage levels in this zone continued to increase suggesting that the
losses in density weren’t due to stress shielding, but instead due to an increase
of remodeling from damage removal in this area. All other reductions in bone
density were significantly less in other regions, with a loss of 4% or lower in all
other GZ. The distal end of the stem had slightly higher losses seen in GZ 3 and
4.
After implementing the resurfacing implant into the model a small amount
of bone loss occurred over all GZ within the first two months following
implantation, however bone density values nearly returned to preoperative levels
by the end of the two year period with a maximum BVF loss under 2% for all GZ.
These changes can be seen in Figure 3-4.
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Figure 3-4 shows the postoperative bone volume fraction changes in the seven different
Gruen zones for the articular surface replacement validation run. The reference BVF
baseline is taken from the day of surgery.

Comparing our results to clinical data, we validated our model at one and
two year postoperative time. These studies all used dual energy X-ray
absorptiometry (DEXA) to measure the small changes in bone mass. At one
year, there were no apparent differences in the percent BMD change found when
comparing our results to Nishioka et al. [61] seen in Figure 3-5. Visual
inspections of the standard deviation results obtained by Nishioka et al. were
used for this determination since the values were not given.
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Figure 3-5 shows a comparison between BMD change results obtained clinically by
Nishioka et al. [61] and our experimental data one year postoperatively for a THR. There
were no apparent differences in any GZ.

Comparing to Nakamura et al, [62] after one year there were no significant
differences in BMD changes after one year postoperatively following THR
surgery n GZ 3, GZ 4, and GZ 5, but the model overpredicted the BMD changes
in GZ 1 (p-value = 0.037), GZ 2 (p-value = 0.010), GZ 6 (p-value = 0.018) and
GZ 7 (p-value = 0.003) as seen in Figure 3-6.
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Figure 3-6 shows a comparison between BMD results obtained clinically by Nakamura et al. [62]
and our experimental data one year postoperatively for a THR. There were statistical similarities
in GZ 3, GZ 4, and GZ 5 and significant differences in GZ 1 (p-value = 0.037), GZ 2 (p-value =
0.010), GZ 6 (p-value = 0.018) and GZ 7 (p-value = 0.003).

After one year, there were no significant differences in the percent BMD
change compared to the results of Arabmotlagh et al. [63] as seen in Figure 3-7.
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Figure 3-7 shows a comparison between BMD change results obtained clinically by
Arabmotlagh et al. [63] and our experimental data one year postoperatively for a THR.
There were no significant differences.

Looking at results from Nakamura et al. [62] once again after two years
postoperative, there were no significant differences in BMD changes after two
years postoperatively following THR surgery in GZ 1, GZ 3, GZ 4, and GZ 5, but
the model again overpredicted the BMD changes found in GZ 2 (p-value =
0.027), GZ 6 (p-value = 0.028), and GZ 7 (p-value = 0.039) which can be seen in
Figure 3-8.
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Figure 3-8 shows a comparison between BMD results obtained clinically by Nakamura et
al. [62] and our experimental data two years postoperatively for a THR. There were
statistical similarities in GZ 1, GZ 3, GZ 4, and GZ 5 and significant differences in GZ 2
(p-value = 0.027), GZ 6 (p-value = 0.028), and GZ 7 (p-value = 0.039).

Comparisons of the model results with those from literature confirm the
validity of the model used in the current study. While there were significant
differences in some regions between our experimental results and those of
Nakamura et al, [62] the clinical data is almost fifteen years old. The model
results were statistically similar to the results from the most current research
groups. Looking at the values from these clinical experiments, the success with
the newer clinical studies shows more bone being retained which could be
attributed to the advancement of hip prosthesis in the last fifteen years. With
current clinical results being similar to our computer simulated model, this
allowed us to evaluate the long term effects of joint replacement as well as the
effects with Alendronate treatment.
47

3.2. Long Term Implant Effects
Both total hip and articular surface replacement models were run
postoperatively for a total of 6 years. For the total hip replacement, reductions in
BVF continued until about four years postoperatively. After four years, GZ 7
maintained about a 30% BVF change, seen in Figure 3-9, due to stress
shielding. Reductions in BVF continued in GZ 5 for three years and then
maintained a BVF loss of about 13%.

Figure 3-9 shows the postoperative bone volume fraction changes in the seven different
Gruen zones for the total hip replacement six years postoperatively. The reference BVF
baseline is taken from the day of surgery.
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While damage levels off for GZ 2-6, it continues to rise for GZ 1 and 7
throughout the six year period, seen in Figure 3-10.

Figure 3-10 shows the postoperative damage change in the seven different Gruen zones
for the total hip replacement six years postoperatively.
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Activation frequency leveled off for all GZ at three to four years
postoperatively as seen in Figure 3-11. The sharper increases for activation
frequency occurred in the distal regions of the stem implant (GZ 3-5) while the
damage also increased, indicating the decrease in porosity is due to the
increased remodeling due to damage occurring in these regions.

Figure 3-11 shows the activation frequency in the seven different Gruen zones for the
total hip replacement six years postoperatively.
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For the articular surface replacement the BVF maintained the levels seen
from the validation run. All GZ BVF changes remained under 2% and can been
seen in Figure 3-12.

Figure 3-12 shows the postoperative bone volume fraction changes in the seven different
Gruen zones for the articular surface replacement six years postoperatively. The
reference BVF baseline is taken from the day of surgery.
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Damage levels in GZ 1 increased rapidly throughout all six years
postoperatively, seen in Figure 3-13, while the other GZ didn’t show any
significant change.

Figure 3-13 shows the postoperative damage change in the seven different Gruen zones
for the articular surface replacement six years postoperatively.
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Overall, activation frequency only showed a slight increase in GZ 1 over
the six year period, seen in Figure 3-14. The sharp increase in damage, and
relatively stable porosity and activation frequency suggest the damage is a result
of increased strains and the mechanical stimulus.

Figure 3-14 shows the activation frequency in the seven different Gruen zones for the
articular surface replacement six years postoperatively.

3.3. Preoperative Alendronate Effects
Implementing Alendronate treatment one year preoperatively for the total
hip replacement model led to an increased BVF of 6% in GZ 1 at the end of the
preoperative period, seen in Table 3-1. Other GZ didn’t experience a significant
change.
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Table 3-1 shows the preoperative end state porosity change for the total hip replacement
between no Alendronate treatment and one year of Alendronate treatment.

THR Preoperative
BVF (%)
Gruen Zone No Treatment Treatment % Difference
1

55%

49%

6%

2

6%

5%

0%

3

5%

5%

0%

4

6%

7%

0%

5

8%

9%

-1%

6

11%

10%

1%

7

6%

6%

0%

Alendronate treatment one year preoperatively with the articular
surface replacement led to an increased BVF of 11% in GZ 1 at the end of
the preoperative period, with smaller increases in all other regions as well,
seen in Table 3-2.
Table 3-2 shows the preoperative end state porosity change for the articular surface
replacement between no Alendronate treatment and one year Alendronate treatment.

ASR Preoperative
BVF (%)
Gruen Zone No Treatment Treatment % Difference
1

57%

46%

11%

2

7%

6%

1%

3

7%

6%

1%

4

7%

6%

1%

5

8%

6%

2%

6

12%

9%

3%

7

7%

6%

2%
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3.4. Postoperative THR Alendronate Treatment Effects
Continuous Alendronate treatment starting one day postoperatively and
lasting for all six years resulted in constant BVF gains for GZ 1 seen in Figure 315. At the end of six years, GZ 1 had gained 23% BVF. The only other region to
show gains was GZ 6 at 2%. Gruen zone 7 lost about 3% BVF while every other
region lost less than 1% BVF.

Figure 3-15 shows the postoperative bone volume fraction changes in the seven different
Gruen zones for the total hip replacement six years postoperatively with continuous
Alendronate treatment. The reference BVF baseline is taken from the day of surgery.
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Continuous treatment for 6 years postoperatively curbed damage across
all GZ by year three as seen in Figure 3-16. This is due in part to the decrease
in resorption area caused by Alendronate, which helps improve bone balance,
decreasing the microdamage further. This increased bone balance increases
bone volume, and the strain and mechanical stimulus decline, decreasing
damage formation. The diminished mechanical stimulus also increased
remodeling activity over time due to the disuse response.

Figure 3-16 shows the postoperative damage change in the seven different Gruen zones
for the total hip replacement six years postoperatively with continuous Alendronate
treatment.
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Activation frequency remained relatively the same across GZ 2-6, while
GZ 1 showed slight gains and GZ 7 increased the most as seen in Figure 3-17.
The increase in activation frequency of GZ 7 and decrease in damage over the
six years still show the prevalence of stress shielding.

Figure 3-17 shows the activation frequency in the seven different Gruen zones for the
total hip replacement six years postoperatively with continuous Alendronate treatment.
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For a total hip replacement with Alendronate treatment starting one day
postoperatively and lasting one year, BVF loss was not as severe as the non
treated model. Significant BVF reduction occurred after treatment had
terminated in year one. At the end of six years, a decrease in BVF for GZ 1
reached 26% and BVF reached a 7% reduction in GZ 5 as seen in Figure 3-18.

Figure 3-18 shows the postoperative bone volume fraction changes in the seven different
Gruen zones for the total hip replacement six years postoperatively with one year
postoperative Alendronate treatment. The reference BVF baseline is taken from the day
of surgery.
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Damage in GZ 7 decreased throughout the six year postoperative period
while damage in GZ 1 slightly increased as seen in Figure 3-19. The first year
saw damage peak for GZ 2-6 while it leveled off starting in year two.

Figure 3-19 shows the postoperative damage change in the seven different Gruen zones
for the total hip replacement six years postoperatively with one year postoperative
Alendronate treatment.
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Activation frequency for GZ 1 and 7 increased during the first year while
all other GZ decreased as seen in Figure 3-20. During the second year, only GZ
1 decreased in activation frequency and by year three the activation frequency
was stable for all GZ. Sharp increases in activation frequency with concurrent
decreases in damage suggest some level of stress shielding for all regions but
GZ 1.

Figure 3-20 shows the activation frequency in the seven different Gruen zones for the
total hip replacement six years postoperatively with one year postoperative Alendronate
treatment.
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Using the preoperative Alendronate treatment for one year combined with
one year postoperative Alendronate treatment, only GZ 1 shows significant
change with an 8% BVF increase over a no treatment scenario at the end of one
year as can be seen in Figure 3-21. After treatment one year postoperatively,
GZ 7 has reduced BVF by about 29% and GZ 5 has reduced BVF by about 6%.

Figure 3-21 shows the postoperative bone volume fraction changes in the seven different
Gruen zones for the total hip replacement six years postoperatively starting Alendronate
treatment one year preoperative and ending one year postoperative. The reference BVF
baseline is taken from the day of surgery without preoperative treatment to visually
compare the differences at postoperative time 0 with pretreatment.
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Damage levels after one year postoperatively start to increase constantly
in GZ 1 as seen in Figure 3-22. In all other regions, damage remains fairly
constant after one year. During the first year, only GZ 7 sees a decrease in
damage.

Figure 3-22 shows the postoperative damage change in the seven different Gruen zones
for the total hip replacement six years postoperatively starting Alendronate treatment one
year preoperative and ending one year postoperative.
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Activation frequency for GZ 1 and 7 increased during the first year while
all other GZ exhibited decreased activation frequency as seen in Figure 3-23.
During the second year, GZ 1 decreased in activation frequency, GZ 6 stayed
about the same, and all other GZ exhibited increased activation frequency. The
first year GZ 7 increased in activation frequency while decreasing in damage,
demonstrating stress shielding. After the second year, GZ 7 saw a gradual
decrease in activation frequency.

Figure 3-23 shows the activation frequency in the seven different Gruen zones for the
total hip replacement six years postoperatively starting Alendronate treatment one year
preoperative and ending one year postoperative.
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3.5. Postoperative ASR Alendronate Treatment Effects
Continuous Alendronate treatment for six years postoperatively with the
articular surface replacement led to an increase of BVF of 26% for GZ 1 by the
end of the six years as seen in Figure 3-24. An increase in BVF of 3% was also
seen in GZ 6. All other GZ remained stable throughout the six year period.

Figure 3-24 shows the postoperative bone volume fraction changes in the seven different
Gruen zones for the articular surface replacement six years postoperatively with
continuous Alendronate treatment. The reference BVF baseline is taken from the day of
surgery.
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The continuous treatment helped curb damage levels across all GZ by
year three, seen in Figure 3-25. Damage in GZ 1 peaked in year one and
asymptotically decreased towards zero.

Figure 3-25 shows the postoperative damage change in the seven different Gruen zones
for the articular surface replacement six years postoperatively with continuous
Alendronate treatment.
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Activation frequency over the six years increased for GZ 1 and also
increased more gradually for GZ 6 as seen in Figure 3-26. All other GZ
experienced little activation frequency change.

Figure 3-26 shows the activation frequency in the seven different Gruen zones for the
articular surface replacement six years postoperatively with continuous Alendronate
treatment.
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Postoperative BVF changes with treatment starting the day of surgery and
ending after one year remained pretty stable throughout the six year period as
seen in Figure 3-27. Initially GZ 1 showed a 3% increase in BVF but declined to
1% at the end of six years. All other GZ experienced losses of less than 2% over
the six year period.

Figure 3-27 shows the postoperative bone volume fraction changes in the seven different
Gruen zones for the articular surface replacement six years postoperatively with one year
postoperative Alendronate treatment. The reference BVF baseline is taken from the day
of surgery.
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Damage levels for the one year postoperative articular surface
replacement model stayed constant with the exception of GZ 1, as seen in
Figure 3-28. Damage levels in GZ 1 gradually increased over the entire six year
period.

Figure 3-28 shows the postoperative damage change in the seven different Gruen zones
for the articular surface replacement six years postoperatively with one year
postoperative Alendronate treatment.
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Activation frequency also remains pretty constant for the entire six years
after one year postoperative Alendronate treatment to the articular surface
replacement model, as seen in Figure 3-29.

Figure 3-29 shows the activation frequency in the seven different Gruen zones for the
articular surface replacement six years postoperatively with one year postoperative
Alendronate treatment.
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Using the preoperative Alendronate treatment for one year and continuing
treatment for one year postoperatively mainly affected the BVF in GZ 1 seen in
Figure 3-30. The BVF for GZ 1 increased to 13% in year one before decreasing
to less than a 1% gain over the six year period. All other GZ had a decrease in
BVF over the six year period of less than 2%.

Figure 3-30 shows the postoperative bone volume fraction changes in the seven different
Gruen zones for the articular surface replacement six years postoperatively starting
Alendronate treatment one year preoperative and ending one year postoperative. The
reference BVF baseline is taken from the day of surgery without preoperative treatment
to visually compare the differences at postoperative time 0 with pretreatment.
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Damage levels for this scenario remained constant throughout the six
years for GZ 2-7 as seen in Figure 3-31. A constant increase in damage for GZ
1 started after year one and continued for the whole simulation.

Figure 3-31 shows the postoperative damage change in the seven different Gruen zones
for the articular surface replacement six years postoperatively starting Alendronate
treatment one year preoperative and ending one year postoperative.
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Activation frequency for the one year preoperative Alendronate treatment
with one year postoperative treatment stayed fairly constant for most GZ seen in
Figure 3-32. A small decrease for GZ 1 happened after year one but then
remained constant for the following years.

Figure 3-32 shows the activation frequency in the seven different Gruen zones for the
articular surface replacement six years postoperatively starting Alendronate treatment
one year preoperative and ending one year postoperative.
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4. Discussion
Bisphosphonate drugs such as Alendronate have recently been
administered in conjunction with a hip arthroplasty [10, 11]. These drugs are
being used in an attempt to prevent the bone loss in the femur as a result of the
implant and surgical procedure. In this study we attempted to directly compare
the long term effects bisphosphonates had on both total hip and articular surface
replacements using a 3-D finite element model of the femur with an adaptive
bone remodeling algorithm incorporating Alendronate treatment. Our results
showed the success of creating a long term total hip and articular surface
replacement model treated with Alendronate.
Clinically, with dual-energy X-ray absorptiometry measurements, it’s
been shown most bone loss occurs in the first few months after THR surgery and
reveals little change after the first postoperative year. Alendronate treatment
could change this effect.
In one study mentioned earlier (section 3.1), Arabmotlagh et al. [63]
monitored patients for one year postoperatively that had undergone a total hip
replacement surgery and measured the bone mineral density (BMD) change
using dual-energy x-ray absorptiometry (DEXA). In this experiment one group
received a placebo, another group received 10mg/day of oral Alendronate for ten
weeks, and another group received 20mg/day for five weeks. After one year, the
group with the placebo helped validate our model since there were no significant
differences when compared to our results. However, this clinical experiment also
lasted a total of six years. When comparing the placebo group to our computer
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model results after six years, GZ 1, GZ 2, GZ 6, and GZ 7 were statistically
similar while GZ 3 – 5 had significant differences (p-values = 0.035, 0.012, 0.001
respectively) as seen in Figure 4-1.

Figure 4-1 shows a comparison between results obtained clinically by Arabmotlagh et al.
[63] and our experimental data six years postoperatively for a THR with no Alendronate
treatment. Statistical similarities were found in GZ 1, GZ 2, GZ 6, and GZ 7 and
significant differences were seen in GZ 3 (p-value = 0.035), GZ 4 (p-value = 0.012), and
GZ 5 (p-value = 0.001).

The results of the experimental treatment group that received the 10
mg/day for ten weeks were fairly consistent to the results from this computational
study after one year of treatment. At the end of one year, the percent change of
BMD of our experimental study was consistent with the clinical results, with one
significant difference in GZ 7 (p-value = 0.004), seen in Figure 4-2. This
discrepancy is largely due to our model still being under Alendronate effects at
this time (one year).
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Figure 4-2 shows a comparison between results obtained clinically by Arabmotlagh et al.
[63] and our experimental data one year postoperatively for a THR with one year
postoperative Alendronate treatment. All regions were statistically similar except one
significant difference seen in GZ 7 (p-value = 0.004).

After six years with the postoperative Alendronate treatment scenarios by
Arabmotlagh et al. compared with the one year treatment from ours, there were
no significant differences found, as can be seen in Figure 4-3.
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Figure 4-3 shows a comparison between results obtained clinically by Arabmotlagh et al.
[63] and our experimental data six years postoperatively for a THR with one year
postoperative Alendronate treatment.

Another study by Nishioka et al. [61] in which we used to validate our
model also evaluated the effects of Alendronate on bone loss caused by stress
shielding after total hip arthroplasty in Japanese patients. The Alendronate was
administered orally at 5 mg/day for one year and measured a change in bone
mineral density ratio using DEXA scans. All model results after one year were
within the range of these clinical results as seen in Figure 4-4. Again, vvisual
inspection of the standard deviation results obtained by Nishioka et al. [61] were
used for this determination since the values were not given.
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Figure 4-4 shows a comparison between results obtained clinically by Nishioka et al. [61]
and our model data one year postoperatively for a THR with one year postoperative
Alendronate treatment.

Comparisons to both studies by Arabmotlagh et al. [63] and Nishioka et al.
[61] showed significant similarities clinically to the results of the current study.
While treatment scenarios, patient bone anatomies, and differing hip implants are
some of the differences between our study results and the clinical results, we are
still able to gain a confidence our models are working and predicting bone
changes correctly. The total hip replacement results acted as a validation for our
model and led to an acceptance for our surface replacement results. Figures
showing the BVF distribution on the bone can be seen in Appendix E for one
year postoperative and in Appendix F for six years postoperative.
An interesting observation occurs between the runs with preoperatively
treated bone to the bone with no preoperative treatment. While initially bone with
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the pretreatment has a higher BVF, especially in GZ 1, after postoperative
treatment the change in BVF between the scenarios was minimal. Damage on
the other hand has some significant long term differences. After the conclusion
of Alendronate treatment, the pretreated bone had a greater increase of damage
over the six year period with both types of implants for GZ 1. At the end of the
six years, the damage was about double that of the bone treated at the start of
surgery in GZ 1 with little change in other GZs. The implications here are that
there is no benefit to pretreating a patient with Alendronate for bone in the Gruen
zones, and that it might actually be worse in the long run for fracture risk in GZ 1
due to the damage buildup. This could be due to increased time exposure before
stopping treatment causing a more brittle bone susceptible to damages after one
year when both the loads are returned to normal and treatment stops at the same
time.
At the end of six years we can draw some comparisons between all the
different scenarios we ran. With regards to BVF, there is little change between
one year preoperative to one year postoperative Alendronate treatment and one
year postoperative Alendronate treatment for a specific implant type, while both
treatment scenarios seem to increase the BVF over no treatment. However,
when comparing between different implant types, the ASR had higher BVF for all
GZs. This is expected since the GZs are defined around a THR stem and for an
ASR, the GZ are distal to the implant. These comparisons can be seen in Figure
4-5.
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Figure 4-5 shows the bone volume fraction (BVF) change comparisons after six years for
the major treatment scenarios. The reference BVF baseline is taken from the day of
surgery without preoperative treatment.

After six years postoperative time, we could also compare damages
between the different Alendronate treatment scenarios. Pretreatment for both
the THR and ASR had a large impact on the damages in GZ 1. Damages in the
distal GZs were higher with the THR while damages in the proximal GZs had
more damage with an ASR given the same treatment scenario. Treatment
scenarios with the THR seemed to decrease the damage for GZ 3, 4, and 5.
These damage comparisons can be seen in Figure 4-6.
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Figure 4-6 shows the damage for the major treatment scenarios after six years.

One finding by Deuel et al. [34] showed high levels of strain adjacent to
the rim of the ASR, similar to Watanabe et al [64]. In the study by Watanabe et
al. stress shielding was observed in the femoral neck, leading to a suggestion
that the losses in bone density due to stress shielding in combination with areas
of stress concentration around the implant could lead to fracture following hip
resurfacing. With our simulations, the effects of Alendronate treatment scenarios
could be compared for the area around the ASR rim as well. Looking at the
strains without any Alendronate treatment we can see a sharp increase right after
implantation with the values steadying about three years postoperative. With
treatment starting the day of surgery the strain lowers, and with pretreatment
strain lowers even more, closer to normal levels. The differences in strain
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around the ASR rim can be seen in Figure 4-7 and pictures of the strain can be
seen in Appendix F.

Figure 4-7 shows the differences in strain adjacent to the ASR rim for the different
treatment scenarios.

Damage follows a similar pattern to the strain with the different treatment
scenarios seen in Figure 4-8. Alendronate treatment drastically reduces the
damage level when being compared to no treatment. Pretreating with
Alendronate seems to show the best damage reduction value.

81

Figure 4-8 shows the differences in damage adjacent to the ASR rim for the different
treatment scenarios.

Interestingly, the BVF adjacent to the rim increased with Alendronate
treatment. Pretreating also seemed to increase the BVF even more, as seen in
Figure 4-9. With this information, it seems as if the Alendronate helped even out
the imbalance of bone resorption to reformation. This helped decrease the
damage in the rim area and maintain lower strain values with the increase of
bone density in the area.
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Figure 4-9 compares the BVF percentage adjacent to the ASR rim for the different
treatment scenarios.

Previous models incorporating this bisphosphonate code [48, 49]
maintained continuous treatment and never looked at the effects after treatment
had stopped. The bisphosphonate code is either turned on or off, with no
lingering effects. However, drugs still remain in the body even after a person has
stopped the intake. The half life of Alendronate in humans is estimated to be
about ten years in length [65]. The current code for bisphosphonates needs to
add in a function over time related to the potency to decrease the effects of
bisphosphonates to correspond with the half life. While the long term results still
fit to clinical numbers, the simulation could become more accurate with this
implemented.
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There are also some limitations to the bone model itself in our study. A
model from the CT scan of the cadaveric bone had an unknown loading history,
and comparisons between the clinical and experimental bone density changes
occurred under estimated loading conditions which may not have been
representative of the individual. Also, the identical loading conditions were used
for the models of both hip resurfacing and total hip replacements, even though
the patient population for resurfacing is generally younger and more active.
Patterns of bone loss were consistent with other clinical and computational
studies however. A limitation with the user material subroutine to our model is
that bone remodeling is a complex process affected by skeletal loading as well
as metabolic and hormonal activities and these factors aren’t accounted for.
Loading changes from the native state following surgery is the most likely factor
contributing to the remodeling rates though. The implants in the model are also
fully bonded to the surrounding bone immediately following implantation, which
has the potential of allowing greater load transfer to the proximal aspect of the
femur than occurs for the total hip replacement clinically.
Even with all these limitations we were able to show the pretreatment of
Alendronate compared to starting treatment the day of surgery may not have
much of an impact on long term bone density for the Gruen Zones. Damage
seems to double with pretreatment compared to no treatment for GZ 1. The
resurfacing implant caused more damage to the proximal GZs while the total hip
replacement caused more damage to the distal zones around the implant stem.
When looking around the resurfacing rim however, pretreatment seems to show
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big changes in the damage, strain, and bone density values when compared to
no treatment and treatment starting the day of surgery. The implication is that
pretreatment may help prevent femoral neck fracture.
Future experiments might want to investigate if offsetting the termination
of Alendronate and the return of full force loads would help decrease the damage
accumulation rate. Also, the addition of the Alendronate half life to better
simulate long term drug effects on the bone might provide higher accuracy.
Additionally, modeling hormonal effects and implementing them into the user
material code could improve the model simulations. A more complete muscle
force set could be added to the femur model as well. While the primary muscles
involved in stress patterns for the proximal aspect of the femur were used, other
muscles such as the quadriceps and iliotibial band have been shown to have
more of an effect on diaphyseal strains [66]. The loading conditions for the
model were also applied under an ideal implant state while implanting into an
actual human will not have the perfect surgical positioning, for example the
implant may not always have the same neck length as the native femur.
Diseases like cancer could also be factored into the model in the future.
Radiation effects on bone remodeling and bone properties could be observed as
well. As newer drugs are produced and more information about remodeling is
discovered, these effects can then be modeled and compared using this
simulation. The user material subroutine could also be used for other bones with
implants to determine similar effects with bisphosphonate treatments and
whether certain treatment scenarios provide any long term benefits.
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Appendix A User Subroutine
subroutine sdvini(statev,coords,nstatv,ncrds,noel,npt,
* layer,kspt)
c
include '/usr/apps/abaqus/6.7-3/site/aba_param_dp.inc'
c
character*80 fname
dimension statev(nstatv),coords(ncrds)
dimension jelarr(110000,2),sdvarr(110000,105)
integer kflag
save kflag,sdvarr,jelarr
c
c

write(*,*) 'kflag = ', kflag
if (kflag.eq.0) then

c
fname='/home/thryce/bmu/taperloc_preop_bis.txt'
intpts=106124
c
open(unit=300,file=fname,status='old')
c
c
do i=1,intpts
read(300,310) jelarr(i,1),jelarr(i,2),(sdvarr(i,j),j=1,105)
310
format(i5,1x,i2,1x,4f12.9,1x,e12.6,1x,3f10.6,1x,100f9.6)
end do
c
kflag=1
write(*,*) 'Finished reading .txt file'
end if
c
if (noel.le.26531) then
if ((noel.gt.19694).and.(noel.le.26531)) then
krownum=((noel-2)*4)+npt
else if (noel.le.19694) then
krownum=((noel-1)*4)+npt
end if
c
do k2=1,105
statev(k2)=sdvarr(krownum,k2)
end do
else
c
c initialize porosity
c
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statev(1)=0.05
statev(1)=0.20

c
c
c initialize minimum principal strain for first,
c
second, and third steps
c
statev(2)=0.0
statev(3)=0.0
statev(4)=0.0
c
c initialize damage potential
c
statev(5)=0.0
c
c initialize equilibrium damage
c
statev(6)=0.03662944
c
c initialize number of refilling and resorbing BMUs
c
statev(7)=0.0
statev(8)=0.0
c
c initialize activation frequency for trif days
c
do k=9,nstatv
statev(k)=0.00670
end do
end if
close (unit=300)
return
end
c
c
c
c
c
subroutine umat(stress,statev,ddsdde,sse,spd,scd,
* rpl,ddsddt,drplde,drpldt,
* stran,dstran,time,dtime,temp,dtemp,predef,dpred,bone,
* ndi,nshr,ntens,nstatv,props,nprops,coords,drot,pnewdt,
* celent,dfgrd0,dfgrd1,noel,npt,layer,kspt,kstep,kinc)
c
include '/usr/apps/abaqus/6.7-3/site/aba_param_dp.inc'
c
character*8 bone
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dimension stress(ntens),statev(nstatv),ddsdde(ntens,ntens),
* stran(ntens),dstran(ntens),props(nprops),s(3),ps(3)
integer trif,tr,ti,tf,lstr
real kb,kc,kd,kr,nf,nr,nfexist,nrexist,do,sa,modulus,nu,
* tstep,minprin,rl1,rl2,rl3,phi,shearmod,bulkmod,lambda,samax,
* q,pi,fs,dt,facur,famax1,famax2,fao,rc,rh,dexist,area,ddotform,
* ddotrep,dcurrent,fadivsa,fa,ab,ac,qb,qc,phc,qnet,dp,maxprin,
* maxmag
c
c elastic properties
c
write(*,*) 'step = ', kstep
c
c
if (statev(1).lt.0.097267787) then
modulus=23440*(1-statev(1))**5.74
else
modulus=14927*(1-statev(1))**1.33
endif
c
nu=props(1)
c
c

specify props for titanium
if (noel.gt.26531) then
modulus=114000
nu=0.33
spd=3
scd=75.
sse=0.8
end if

c
bulkmod=modulus/(3*(1-2*nu))
shearmod=modulus/(2*(1+nu))
lambda=bulkmod-2*shearmod/3
c
c elastic stiffness
c
c
c
ddsdde(1,1)=2*shearmod+lambda
ddsdde(2,2)=2*shearmod+lambda
ddsdde(3,3)=2*shearmod+lambda
ddsdde(4,4)=shearmod
ddsdde(5,5)=shearmod
ddsdde(6,6)=shearmod
ddsdde(1,2)=lambda
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ddsdde(1,3)=lambda
ddsdde(2,1)=lambda
ddsdde(2,3)=lambda
ddsdde(3,1)=lambda
ddsdde(3,2)=lambda
c
c initialze stress for the current step
c
do k1=1,ntens
stress(k1)=0.0
end do
c
c calculate stress
c
do k1=1,ntens
do k2=1,ntens
stress(k2)=stress(k2)+ddsdde(k2,k1)*(stran(k1)+dstran(k1))
end do
end do
c
c proceed through remodeling algorithm for elements defining bone
c
c
c
c calculate minimum and maximimum principle strains
c
c transform current steps to tstep to define first, second, and
c third steps of input file
c
c store maximum magnitude principle strain as state variable for each step
c
if (kstep.eq.1) then
if (noel.eq.1) then
if (npt.eq.1) then
write(*,*) 'calculating strains'
endif
endif
endif
c
c
if (noel.le.26531) then
do k1=1,ntens
s(k1)=stran(k1)+dstran(k1)
end do
lstr=2
call sprinc(s,ps,lstr,ndi,nshr)
94

if (abs(ps(1)).ge.abs(ps(2))) then
maxmag=ps(1)
else
maxmag=ps(2)
endif
c
tstep=abs((real(kstep))/3-int(kstep/3))
if ((tstep.gt.0.2).and.(tstep.lt.0.5)) then
statev(2)=maxmag
else if ((tstep.gt.0.5).and.(tstep.lt.0.8)) then
statev(3)=maxmag
else if (tstep.lt.0.2) then
statev(4)=maxmag
endif
c
c
c
c
c specify activation frequency at equilibrium
fao=0.00670
c
c
c calculate time for resorptive phase of remodeling cycle, tr
c calculate time for reversal phase of remodeling cycle, ti
c calculate time for refilling phase of remodeling cycle, tf
c calculate total time of remodeling cycle, trif
c
tr=25
ti=5
tf=64
trif=tr+ti+tf
c
c initialize the existing number of refilling and resorbing BMUs
c specify existing number of refilling and resorbing BMUs
c
if (kstep.eq.1) then
if (noel.eq.1) then
if (npt.eq.1) then
write(*,*) 'calculating BMUs'
endif
endif
endif
c
c
if (kstep.eq.1) then
statev(7)=fao*tf
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statev(8)=fao*tr
endif
nfexist=statev(7)
nrexist=statev(8)
c
c
********************************************************
c
c proceed through porosity update after the third step
c
c
c
if ((kstep.ne.1).and.(tstep.lt.0.2)) then
c
c calculate damage potential
c store damage potential as state variable
c calculate rate of damage formation
c calculate rate of damage repair
c calculate current day damage
c store current day damage as state variable
c
c specifiy equilibrium damage
c initialize existing damage
c specify existing damage
c
do=0.03662944
dexist=statev(6)
c
c specify coefficients for damage formation equation and
c
activation frequency equations
c
c
kd=40.2
kd=185000.
kr=-1.6
c
kb=13000000.
kb=65000000000.
c
kc=0.0000004325
kc=0.0000000000938
c
c
c specify loading rate for load case 1, rl1, load case 2, rl2,
c
and load case 3, rl3
c specify exponent for damage formation equation
c
if (kstep.le.270) then
rl1=2000.
rl2=2000.
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c

rl3=16.
else if ((kstep.le.1095).and.(kstep.gt.270)) then
rl1=2250.
rl2=2250.
rl3=18.
else
rl1=2500.
rl2=2500.
rl3=20.
endif
q=2.89
q=4

c
c
c specify value for pi
c specify repair specificity factor
c specify time step
c
pi=3.1415926535897932385
fs=5.0
dt=1.0
c
c specify current day activation frequency
c specify max activation frequency/max specific surface area
c
facur=statev(9)
c
famax1=2.15
famax1=0.50
c
famax2=4.15
famax2=1.15
samax=4.1905
c
c specify cement line radius
c specify haversian radius
c
rc=0.095
rh=0.020
c
c
c
phi=((abs(statev(2)))**q)*rl1+((abs(statev(3)))**q)*rl2
*
+((abs(statev(4)))**q)*rl3
statev(5)=phi
if (statev(1).le.0.20) then
area=pi*rc**2
else
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area=0.5*pi*rc**2
endif
ddotform=kd*phi
ddotrep=dexist*facur*area*fs
dcurrent=dexist+(ddotform-ddotrep)*dt
if (dcurrent.ge.800) then
dcurrent=800
endif
statev(6)=dcurrent
c
c
c
c
c
c
c

update current activation frequency
calculate specific surface area
add in potency for bisphosphonate treatment
update activation frequency by a reduction of P
*

*
c

fadivsa=(fao*(famax1/samax))/(fao+(famax1-fao)
*exp(kr*famax1*(dcurrent-do)/do))
if (dcurrent.lt.do) then
fadivsa=(fao/samax)*(dcurrent/do)
endif
sa=((((28.8*statev(1)-101)*statev(1)+134)*statev(1)
-93.9)*statev(1)+32.3)*statev(1)
if (phi.lt.0.000000865) then
if (phi.lt.0.0000000001875) then
fadivsa=fadivsa+(famax2/samax)/(1+exp(kb*(phi-kc)))
endif
fa=fadivsa*sa
if (kstep.le.1092) then
P=1*(1-exp(-5.0*nrexist))
fa=(1-P)*fadivsa*sa
endif

c
c update activation frequency history
c
do k1=trif+9,10,-1
statev(k1)=statev(k1-1)
end do
c
c store current activation frequency as state variable
c
statev(9)=fa
c
c add in bisphosphonate reduction to trabecular bone
c calculate daily amount of bone added per refilling BMU
c calculate daily amount of bone removed per resorbing BMU
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c include decreased resorption after specified time
c include less refilling on trabecular surfaces in disuse
c
ac=area
if (kstep.le.1092) then
if (statev(1).gt.0.20) then
ac=area*(10/13)
endif
endif
if (statev(1).le.0.20) then
area=pi*(rc**2-rh**2)
endif
ab=area
qb=ab/tf
qc=ac/tr
if (statev(1).gt.0.20) then
if (phi.lt.0.0000000001875) then
qb=(0.5+0.5*phi/0.0000000001875)*ab/tf
endif
endif
c
c calculate number of refilling BMUs for current day
c calculate number of resorbing BMUs for current day
c store number of refillilng and resorbing BMUs as state variables
c
nf=nfexist+(statev(tr+ti+9)-statev(trif+9))*dt
nr=nrexist+(statev(9)-statev(tr+9))*dt
if (nf.lt.0.0) then
nf=0.0
endif
if (nr.lt.0.0) then
nr=0.0
endif
statev(7)=nf
statev(8)=nr
c
c calculate net amount of bone added per day
c
phc=0.04432132964
qnet=(qb*nf)-(qc*nr)
if (statev(1).le.0.20) then
qnet=(qb*nf)-(1-phc)*(qc*nr)
endif
c
c calculate change in porosity
c update porosity
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c
dp=-qnet*dt
statev(1)=statev(1)+dp
c
c specify limits for porosity
c check porosity against limits
c specify state variables to plot
c
c
write(*,*) 'delta porosity = ', dp
c
write(*,*) 'final porosity = ', statev(1)
c
write(*,*) 'activation freq = ', statev(9)
c
write(*,*) 'damage = ', statev(6)
ulim=0.99
blim=0.05
if (statev(1).ge.ulim) then
statev(1)=ulim
else if (statev(1).le.blim) then
statev(1)=blim
endif
endif
spd=statev(1)
sse=statev(9)
scd=statev(6)*(0.95/(1-statev(1)))
c
spd=statev(5)
c
sse=modulus
c
scd=statev(6)
c
spd=statev(2)
c
sse=statev(3)
c
scd=statev(4)
endif
return
end
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Appendix B Extracting Results
C============================================================
=========
C
C This program extracts state variables from a .fil file
C
C Reference Abaqus Standard User's Manual Volume 1 Sections 5.1.2,3
C and Abaqus Example Problems Manual Section 11.1.3 V6.3
C============================================================
=========
C
C Define variables and arrays
C
SUBROUTINE ABQMAIN
INCLUDE '/usr/apps/abaqus/6.7-3/site/aba_param_dp.inc'
CHARACTER*80 FNAME, FOUT
DIMENSION STVAR(200)
DIMENSION ARRAY(513),JRRAY(NPRECD,513),LRUNIT(2,1)
EQUIVALENCE (ARRAY(1),JRRAY(1,1))
C
C Name output file and results file
C
WRITE(*,*) 'ENTER OUTPUT FILENAME'
READ(*,*) FOUT
WRITE(*,*) 'ENTER .FIL FILENAME WITHOUT .FIL EXT'
READ(*,*) FNAME
C
FNAME=''
C
C Open output file
C
OPEN(UNIT=400,FILE=FOUT,STATUS='NEW')
C
C Intiliaze ABAQUS interface with FORTRAN
C See Abaqus manual section 5.1.3 version 6.3
C
NRU=1
LRUNIT(1,1)=8
LRUNIT(2,1)=2
LOUTF=0
CALL INITPF(FNAME,NRU,LRUNIT,LOUTF)
JUNIT=8
CALL DBRNU(JUNIT)
C
C Read records from the results file (*.fil).
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C
C

DO 100 K1=1,99999999
CALL DBFILE(0,ARRAY,JRCD)
write(*,*) 'jrcd', jrcd
IF (JRCD.NE.0) GO TO 110

C
C Get record key for current line.
C
KEY=JRRAY(1,2)
C
write(*,*) 'KEY= ',KEY
C
C Retrieve element and int point # from element header record (key=1)
C See Abaqus manual section 5.1.2 version 6.3 for keys
C
IF (KEY.EQ.1) THEN
JEL=JRRAY(1,3)
JPNT=JRRAY(1,4)
C
C Retrieve solution dependent state variables (key=5)
C
ELSE IF (KEY.EQ.5) THEN
DO I=1,105
STVAR(I)=ARRAY(I+2)
END DO
WRITE(400,80) JEL,JPNT,(STVAR(J),J=1,105)
80
FORMAT(I5,1X,I2,1X,4F12.9,1X,E12.6,1X,3F10.6,1X,100F9.6)
END IF
100 CONTINUE
110 CONTINUE
C
CLOSE (UNIT=400)
STOP
END
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Appendix C Extracting File
C============================================================
=========
C
C The program extracts the state variables from a bone adaptation
C model for given region per 75 days into a text file.
C
C============================================================
=========
C
C Define variables and arrays
C
INCLUDE '/usr/apps/abaqus/6.7-3/site/aba_param_dp.inc'
CHARACTER*80 FNAME, OUTNAME
INTEGER NOELEM, JELDUM, JCT, INCSTART, INCSTOP, LAST
REAL NOSTV
DIMENSION JELEM(1000), STVAR(1000), AVGSTV(1000)
DIMENSION ARRAY(513),JRRAY(NPRECD,513),LRUNIT(2,1)
EQUIVALENCE (ARRAY(1),JRRAY(1,1))
C
C Open input file and read in results file, number of elements in group
C of interest, and list of element numbers making up group.
C
OPEN(UNIT=300,FILE='taperlocpostopgruen1.isv',STATUS='OLD')
READ(300,500) FNAME
PRINT *, FNAME
READ(300,500) OUTNAME
PRINT 502, 'Output file is ', OUTNAME
READ(300,501) INCSTART
PRINT 503, 'Start increment is ',INCSTART
READ(300,501) LAST
PRINT *, LAST
READ(300,501) NOELEM
PRINT 503, 'Number of Elements in Group = ', NOELEM
DO 15 L=1,NOELEM
READ(300,501) JELDUM
JELEM(L)=JELDUM
15 CONTINUE
500 FORMAT(A)
501 FORMAT(I)
C
C Open output file
C
OPEN(UNIT=400,FILE=OUTNAME,STATUS='NEW')
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C
C Check to see if input file was read correctly.
C
502 FORMAT(A20,A20)
503 FORMAT(A30,I)
DO 16 L=1,NOELEM
PRINT *, 'ELEM #', JELEM(L)
16 CONTINUE
C
C Intiliaze ABAQUS interface with FORTRAN
C
NRU=1
LRUNIT(1,1)=8
LRUNIT(2,1)=2
LOUTF=0
CALL INITPF(FNAME,NRU,LRUNIT,LOUTF)
JUNIT=8
CALL DBRNU(JUNIT)
C
C Heading for output file
C
WRITE (400,104) 'step', 'fa', 'porosity', 'damage'
104 FORMAT(1X, A4, T6, A7, T17, A9, T27, A8)
C
C Call the desired steps from which data is extracted.
C
C Loop through calls of step number (e.g. 150,300,450,600)
C
NSTEP=INCSTART
INCSTOP=LAST
NINC=0
DO 2000 J10=1,50
IF (NSTEP.GT.INCSTOP) GO TO 2001
K=1
JCT=0
CALL POSFIL(NSTEP,NINC,ARRAY,JRCD)
C
WRITE(*,*) 'JRCD = ', JRCD
WRITE(*,*) 'STEP ', NSTEP
C
C Set state variables equal to zero.
C
NOSTV=3
DO J=1,NOSTV
STVAR(J)=0.0
END DO
C
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C Read records (element, state variables) from the results
C file (*.fil). Cover a maximum of 10 million records.
C
DO 1000 K100=1,10000
DO 1000 K1=1,9999
C
WRITE(*,*) 'K100 ', K100
C
WRITE(*,*) 'K1 ', K1
CALL DBFILE(0,ARRAY,JRCD)
C
write(*,*) 'jrcd', jrcd
IF (K.GT.NOELEM) GO TO 1001
C
C Get record key for current line.
C
KEY=JRRAY(1,2)
C
write(*,*) 'KEY= ',KEY
C
C Retrieve element number form record line
C
IF (KEY.EQ.1) THEN
JEL=JRRAY(1,3)
JPT=JRRAY(1,4)
C
C
C
ELSE IF (KEY.EQ.14) THEN
C
write(*,*) 'JEL= ',JEL
C
write(*,*) 'JELEM= ',JELEM(1)
IF (JEL.EQ.JELEM(K)) THEN
DO I=1,NOSTV
STVAR(I)=STVAR(I)+ARRAY(I+2)
END DO
C
WRITE(*,*) 'ELEM #', JEL
C
WRITE(*,*) 'INTEG #', JPT
C
WRITE(*,*) 'ARRAY ',ARRAY(3)
C
WRITE(*,*) 'VARIA ',STVAR(1)
K=K+1
END IF
END IF
1000 CONTINUE
1001 CONTINUE
C
C Calculate the average state variables for all integration points.
C
C
DO L=1,NOSTV
AVGSTV(L)=STVAR(L)/(NOELEM)
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END DO
C
WRITE(400,504) NSTEP, (AVGSTV(J),J=1,NOSTV)
504 FORMAT(I5,1X,F9.6,1X,F9.6,1X,F9.6)
NSTEP=NSTEP+1092
2000 CONTINUE
2001 CONTINUE
CLOSE (UNIT=400)
STOP
END
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Appendix D ISV File
taperloc_postop
taperlocpostopgruen12250.txt
1092
2184
20
19734
19738
19877
20406
20486
20497
20519
20523
20529
20533
20565
21104
21199
21205
21240
21241
21845
21948
21958
21991
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Appendix E One Year Porosity Pictures

Figure E-1 shows porosity for the total hip replacement one year postoperatively for no
bisphosphonate treatment (left), treatment starting day of surgery (middle), and treatment
starting one year preoperatively (right).
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Figure E-2 shows porosity for the articular surface replacement one year postoperatively
for no bisphosphonate treatment (left), treatment starting day of surgery (middle), and
treatment starting one year preoperatively (right).
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Appendix F Six Year Porosity Pictures

Figure F-1 shows porosity for the total hip replacement six years postoperatively for
treatment starting day of surgery (left) and treatment starting one year preoperatively
(right).
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Figure F-2 shows porosity for the articular surface replacement six years postoperatively
for treatment starting day of surgery (left), and treatment starting one year preoperatively
(right).
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Appendix G Six Year Strain Pictures

Figure G-1 shows the strain adjacent to the articular surface replacement rim six years
postoperatively for no treatment (top), treatment starting day of surgery (middle), and
treatment starting one year preoperatively (bottom).
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